Berkeley Lights Announces Opto™ Assure For Early Manufacturability Assessment of Antibody Therapeutics

EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the launch of Opto Assure, a series of assays that provides yield and product quality data at an earlier stage in cell line development. The first of the series enables direct detection of product aggregates, ensuring a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process. With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.
 
Cell line development has become more challenging with the emergence of complex antibody therapeutic formats. These highly engineered proteins are prone to quality issues including aggregation, by-products, and post-translational modifications, which impact drug manufacturability, shelf life, and safety. Berkeley Lights enhances its technology leadership position in cell line development by going beyond titer assessment in the clone selection process. Opto Assure helps minimize risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality.
 
“We’re excited to empower manufacturers of complex therapeutics, such as bispecifics, to develop better production cell lines faster. As we build out the Opto Assure series, customers can look forward to added capabilities that further reduce resources spent on preventing product failures downstream and ensure a more efficient process,” said John Proctor, Ph.D., SVP of Antibody Therapeutics at Berkeley Lights.
 
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.